196 related articles for article (PubMed ID: 30919894)
1. Comparative effectiveness of allopurinol and febuxostat for the risk of atrial fibrillation in the elderly: a propensity-matched analysis of Medicare claims data.
Singh JA; Cleveland JD
Eur Heart J; 2019 Sep; 40(36):3046-3054. PubMed ID: 30919894
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in older adults: an analysis of Medicare claims data.
Singh JA; Cleveland JD
Ann Rheum Dis; 2017 Oct; 76(10):1669-1678. PubMed ID: 28584186
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
Singh JA; Akhras KS; Shiozawa A
Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969
[TBL] [Abstract][Full Text] [Related]
4. Allopurinol and the risk of atrial fibrillation in the elderly: a study using Medicare data.
Singh JA; Yu S
Ann Rheum Dis; 2017 Jan; 76(1):72-78. PubMed ID: 27165177
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of allopurinol versus febuxostat for preventing incident dementia in older adults: a propensity-matched analysis.
Singh JA; Cleveland JD
Arthritis Res Ther; 2018 Aug; 20(1):167. PubMed ID: 30075731
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study.
Zhang M; Solomon DH; Desai RJ; Kang EH; Liu J; Neogi T; Kim SC
Circulation; 2018 Sep; 138(11):1116-1126. PubMed ID: 29899013
[TBL] [Abstract][Full Text] [Related]
7. Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study.
Kang EH; Choi HK; Shin A; Lee YJ; Lee EB; Song YW; Kim SC
Rheumatology (Oxford); 2019 Dec; 58(12):2122-2129. PubMed ID: 31098635
[TBL] [Abstract][Full Text] [Related]
8. Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.
Mitri G; Wittbrodt ET; Turpin RS; Tidwell BA; Schulman KL
J Manag Care Spec Pharm; 2016 Apr; 22(4):326-36. PubMed ID: 27023686
[TBL] [Abstract][Full Text] [Related]
9. Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data.
Singh JA; Cleveland JD
Ann Rheum Dis; 2020 Apr; 79(4):529-535. PubMed ID: 32024648
[TBL] [Abstract][Full Text] [Related]
10. Comparing Cardiovascular Safety of Febuxostat and Allopurinol in the Real World: A Population-Based Cohort Study.
Su CY; Shen LJ; Hsieh SC; Lin LY; Lin FJ
Mayo Clin Proc; 2019 Jul; 94(7):1147-1157. PubMed ID: 31272565
[TBL] [Abstract][Full Text] [Related]
11. Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
Chung TT; Yu KH; Kuo CF; Luo SF; Chiou MJ; Lan WC; Chen JS; Tseng WY; Hsieh AH; Wang LC
Arthritis Res Ther; 2019 Sep; 21(1):210. PubMed ID: 31533805
[TBL] [Abstract][Full Text] [Related]
12. New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert.
Choi H; Neogi T; Stamp L; Dalbeth N; Terkeltaub R
Arthritis Rheumatol; 2018 Nov; 70(11):1702-1709. PubMed ID: 29869840
[TBL] [Abstract][Full Text] [Related]
13. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
[TBL] [Abstract][Full Text] [Related]
14. Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout: an 8-year retrospective cohort study.
Kim A; Kim Y; Kim GT; Ahn E; So MW; Lee SG
Clin Rheumatol; 2020 Dec; 39(12):3769-3776. PubMed ID: 32458236
[TBL] [Abstract][Full Text] [Related]
15. Adherence and persistence to urate-lowering therapies in the Irish setting.
McGowan B; Bennett K; Silke C; Whelan B
Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study.
Chou HW; Chiu HT; Tsai CW; Ting IW; Yeh HC; Huang HC; Kuo CC;
Nephrol Dial Transplant; 2018 Sep; 33(9):1620-1627. PubMed ID: 29165620
[TBL] [Abstract][Full Text] [Related]
17. Febuxostat and atrial fibrillation.
Kuwabara M; Borghi C; Johnson RJ
Eur Heart J; 2020 Aug; 41(30):2916-2917. PubMed ID: 32227166
[No Abstract] [Full Text] [Related]
18. Gout and chronic pain in older adults: a Medicare claims study.
Singh JA; Cleveland JD
Clin Rheumatol; 2019 Jul; 38(7):1953-1960. PubMed ID: 30927116
[TBL] [Abstract][Full Text] [Related]
19. Prescription pattern of urate-lowering therapy in Korean gout patients: data from the national health claims database.
Kim JW; Kwak SG; Park SH
Korean J Intern Med; 2018 Jan; 33(1):228-229. PubMed ID: 28823114
[No Abstract] [Full Text] [Related]
20. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
